Program
ICP-332
A development code. Also written as “ICP-332 Tablets”.
Its studies are mostly in Dermatitis, Atopic · Psoriasis · Chronic Urticaria · Vitiligo, led by InnoCare Pharma.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| InnoCare Pharma | 74 open or running | phase 3since Dec 25, 2024 | May 22, 2022 | Nov 25, 2026phase 3 · NCT06775860 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 22, 2022First study: phase 1 study in Healthy SubjectsFirst studyNCT05399030 · 72 enrolled · China
- Jan 10, 2023Phase 2 study in Moderate to Severe Atopic DermatitisNCT05702268 · 75 planned · China
- Jul 28, 2024Phase 1 study in Healthy SubjectsNCT06530966 · 24 enrolled · United States
- Dec 25, 2024Phase 3 study in Dermatitis, AtopicNCT06775860 · 552 planned · China
- Jun 23, 2025Phase 3 study in Non Segmental VitiligoNCT07047612 · 603 planned · China
- Nov 19, 2025Phase 2 study in Plaque PsoriasisNCT07251998 · 182 enrolled · China
- Jan 23, 2026Phase 3 study in Chronic UrticariaNCT07378527 · 344 planned · China
Ahead
- Nov 25, 2026Primary completion: phase 3 study in Dermatitis, AtopicNCT06775860
- Sep 2028Primary completion: phase 3 study in Chronic UrticariaNCT07378527
- Apr 2029Primary completion: phase 3 study in Non Segmental VitiligoNCT07047612
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07378527Chronic Urticaria · China | 3 | Recruiting | Sep 2028 | 344 |
| NCT07251998Plaque Psoriasis · China | 2 | Completed | Oct 30, 2026 | 182 |
| NCT07047612Non Segmental Vitiligo · China | 3 | Recruiting | Apr 2029 | 603 |
| NCT06775860Dermatitis, Atopic · China | 3 | Recruiting | Nov 25, 2026 | 552 |
| NCT06530966Healthy Subjects · United States | 1 | Completed | Nov 8, 2024 | 24 |
| NCT05702268Moderate to Severe Atopic Dermatitis · China | 2 | Recruiting | Jul 30, 2023 | 75 |
| NCT05399030Healthy Subjects · China | 1 | Completed | Jan 30, 2022 | 72 |
How it is read
Names in the registry
- “ICP-332 Tablets”, 8 entries
- “ICP-332”, 2 entries
Codes read as this program: ICP332.
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 2 studies
- Psoriasis, 1 study
- Chronic Urticaria, 1 study
- Vitiligo, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.